Skip to content

US · ILMN · MEDICAL - DIAGNOSTICS & RESEARCH

Illumina, Inc. (ILMN) intrinsic value and stock valuation

$192.82as of 2026-11-21 · Mkt cap 28.44B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Illumina, Inc. DCF and intrinsic value

InvestorsCraft values ILMN with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from ILMN’s statements →

Illumina, Inc. Graham Number

Graham Number: $46.56d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Diagnostics & Research San Diego, CA 92122 illumina.com

How the business is doing

Fiscal 2010–2025, USD

Revenue
$4.34B+4.1% 5y CAGRd
20102025
Net income
$850M-3.2% 5y CAGRd
20102025
Free cash flow
$931M+2% 5y CAGRd
20102025
Total equity
$2.72B-10% 5y CAGRd
20102025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2010–2025, USD
20252024202320222021
Revenue$4.34B$4.37B$4.5B$4.53B$3.24B
Operating income$864M-$-833M-$-1.07B-$-123M$580M
Net income$850M-$-1.22B-$-1.16B$762M$656M
EPSd$5.45M-$-7.69M-$-7.35M$5.05M$4.43M
Operating cash flow$1.08B$837M$478M$545M$1.08B
Capital expenditure-$-148M-$-128M-$-195M-$-208M-$-189M
Free cash flow$931M$709M$282M$337M$891M
Total assets$6.64B$6.3B$10.1B$15.2B$7.59B
Total debt$2.55B$2.62B$2.26B$2.54B$1.91B
Net debt$1.14B$1.5B$1.21B$1.31B$96M
Total equity$2.72B$2.37B$5.75B$10.7B$4.69B
Cash and short-term investments$1.63B$1.22B$1.05B$1.34B$3.47B
Income statement
20252024202320222021
Revenue$4.34B$4.37B$4.5B$4.53B$3.24B
Cost of revenue$1.45B$1.51B$1.76B$1.37B$1.04B
Gross profit$2.89B$2.86B$2.74B$3.15B$2.2B
Research and development expenses$951M$1.17B$1.35B$1.19B$682M
Selling, general and administrative expenses$1.08B$1.09B$1.61B$2.09B$941M
Other expenses$0.00$1.43B$847M$0.00$0.00
Operating expenses$2.03B$3.69B$3.81B$3.28B$1.62B
Cost and expenses$3.47B$5.21B$5.57B$4.65B$2.66B
Interest income$40M$46M$58M$0.00$41M
Interest expense$101M$100M$77M$61M$49M
Depreciation and amortization$270M$354M$432M$251M$187M
Ebitda$1.46B-$-725M-$-608M$1.2B$1.09B
Operating income$864M-$-833M-$-1.07B-$-123M$580M
Total other income/expenses, net$222M-$-346M-$-48M$1.01B$276M
Income before tax$1.09B-$-1.18B-$-1.12B$884M$856M
Income tax expense$236M$44M$44M$122M$200M
Net income$850M-$-1.22B-$-1.16B$762M$656M
Weighted average shares outstanding$155M$159M$158M$150M$147M
Weighted average diluted shares outstanding$156M$159M$158M$151M$148M
Balance sheet
20252024202320222021
Cash and short-term investments$1.63B$1.22B$1.05B$1.34B$3.47B
Net receivables$854M$751M$752M$664M$487M
Inventory$564M$547M$587M$431M$372M
Total current assets$3.29B$2.75B$2.61B$2.71B$4.48B
Property, plant and equipment, net$1.13B$1.23B$1.55B$1.7B$1.45B
Goodwill and intangible assets$1.32B$1.41B$5.54B$10.4B$1.04B
Long-term investments$338M$227M$196M$213M$418M
Total non-current assets$3.36B$3.56B$7.5B$12.5B$3.1B
Total assets$6.64B$6.3B$10.1B$15.2B$7.59B
Accounts payable$240M$221M$245M$332M$192M
Short-term debt$577M$578M$86M$71M$562M
Deferred revenue$270M$260M$252M$234M$186M
Total current liabilities$1.59B$1.55B$1.57B$1.09B$1.24B
Long-term debt$1.98B$2.04B$2.18B$2.47B$1.34B
Deferred revenue, non-current$0.00$67M$0.00$0.00$44M
Total non-current liabilities$2.34B$2.38B$2.8B$3.38B$1.65B
Capital lease obligations$564M$554M$773M$845M$671M
Total liabilities$3.92B$3.93B$4.37B$4.48B$2.89B
Common stock$2M$2M$2M$2M$2M
Retained earnings-$-392M-$-1.24B-$-19M$5.49B$4.72B
Accumulated other comprehensive income (loss)-$-10M$22M-$-1M$17M$2M
Total equity$2.72B$2.37B$5.75B$10.7B$4.69B
Total investments$553M$320M$202M$320M$2.08B
Total debt$2.55B$2.62B$2.26B$2.54B$1.91B
Net debt$1.14B$1.5B$1.21B$1.31B$96M
Cash flow statement
20252024202320222021
Net income$850M-$-1.22B-$-1.16B$762M$656M
Depreciation and amortization$270M$354M$432M$251M$187M
Stock-based compensation$275M$370M$380M$754M$194M
Change in working capital-$-153M-$-483M-$-90M-$-152M$73M
Accounts receivable-$-108M-$-25M-$-40M-$-164M$89M
Inventory-$-17M$19M-$-20M-$-58M-$-12M
Accounts payable$2M-$-4M-$-44M$60M$40M
Net cash provided by operating activities$1.08B$837M$478M$545M$1.08B
Investments in property, plant and equipment-$-148M-$-128M-$-195M-$-208M-$-189M
Acquisitions, net-$-10M$2M-$-29M-$-2.44B-$-98M
Net cash used for investing activities-$-55M-$-178M-$-231M-$-1.07B-$-554M
Common stock issued$44M$56M$67M$60M$61M
Common stock repurchased-$-742M-$-116M$0.00$0.00-$-736M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-744M-$-570M-$-1.21B-$-51M-$-766M
Net change in cash$291M$79M-$-963M-$-578M-$-232M
Cash at end of period$1.42B$1.13B$1.05B$1.23B$1.81B
Operating cash flow$1.08B$837M$478M$545M$1.08B
Capital expenditure-$-148M-$-128M-$-195M-$-208M-$-189M
Free cash flow$931M$709M$282M$337M$891M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Illumina, Inc.

        Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sectors to integrate genomic insights into both research and clinical environments, with applications spanning critical fields like life sciences, cancer diagnostics, reproductive health, agriculture, and innovative new domains. Illumina's portfolio encompasses specialized instrumentation and necessary consumables for genetic analysis, alongside comprehensive genotyping and sequencing services. They also offer instrument maintenance agreements, collaborate through development and licensing deals, and perform cancer detection tests. Its diverse clientele comprises leading genomic research facilities, universities, state-funded laboratories, medical centers, pharmaceutical and biotechnology firms, commercial molecular diagnostic providers, and businesses focused on consumer genomics. Illumina employs a two-pronged distribution strategy, selling directly to clients across North America, Europe, Latin America, and the Asia-Pacific. Additionally, it partners with life-science distributors to reach markets in Europe, the Asia-Pacific, Latin America, the Middle East, and Africa. Established in 1998, the company maintains its corporate headquarters in San Diego, California.

        CEO
        Jacob Thaysen
        Employees
        8.6K
        Beta
        1.47

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Illumina, Inc. (ILMN)?

        Illumina, Inc. (ILMN) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is ILMN undervalued?

        ILMN trades at a price of $192.82 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.